Absolute CD4 Vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 5, 2004, Pages 1028-1033

  Gebo, Kelly A ^a   Gallant, Joel E ^a   Keruly, Jeanne C ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; CD4; CD4 ; Opportunistic illness; Prophylaxis

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; BINOMIAL DISTRIBUTION; DECISION MAKING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 3342924015     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408150-00005     Document Type: Article

References (23)

1. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA. 1992;267:1798-1805.
2. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13:1933-1942.
3. Phair J. Munoz, Detels R, et al. The risk of pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990;322:161-165.
4. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA. 1988;259:1185-1189.
5. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327:1643-1648.
6. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:1332-1338.
7. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:223-231.
8. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA. 1998;277:1962-1969.
10. February 4 2002 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. (http://aidsinfo. nih.gov). Accessed April 1, 2004.
11. Centers for Disease Control. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR Morb Mortal Wkly Rep. 1992;41(RR-8):1-17.
12. Simson E, Groner W. Variability in absolute lymphocyte counts obtained by automated cell counters. Cytometry. 1995;22:26-34.
13. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165:352-363.
14. Hughes MD, Stein DS, Gundacker HM, et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994;169: 28-36.
15. Taylor JM, Fahey JL, Detels R, et al. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2:114-124.
16. Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS. 1991;5:365-372.
17. Le TP, Tribble DR, Zhou SYJ, et al. Clinical significance of discordant CD4 count and CD4 percentage in HIV-infected individuals. AIDS. 1997; 11:1395-1396.
18. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr. 1998;17(suppl 1):S38-S41.
19. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
20. Long JS. Regression Models for Categorical and Linear Dependent Variables. Thousand Oaks, CA: Sage Publications; 1997.
21. Mofenson LM, Korelitz J, Meyer WA III, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175:1029-1038.
22. Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 1998;17:18-23.
23. Zurlo JJ, Wood L, Mackrell Gaglione M, et al. Effect of splenectomy on T lymphocyte subsets in patients infected with the human immunodeficiency virus. Clin Infect Dis. 1995;20:768-771.